Risperidone Long Acting Injectable (LAI)

DRUG2 trials

Sponsors

Janssen-Cilag International NV, Janssen Pharmaceutica N.V., Belgium

Conditions

Bipolar DisorderPsychotic DisordersSchizophrenia

Phase 3

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

CompletedNCT00216476

Janssen-Cilag International NVPsychotic Disorders, Schizophrenia

Start: 2004-10-31End: 2007-11-30Updated: 2014-04-16

A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

CompletedNCT00391222

Janssen Pharmaceutica N.V., BelgiumBipolar Disorder

Start: 2006-11-30End: 2009-04-30Updated: 2014-05-09